Tegsedi (inotersen) — Medica

Initial criteria

• age ≥ 18 years
• patient has a transthyretin pathogenic variant as confirmed by genetic testing
• patient has symptomatic polyneuropathy
• patient does not have a history of liver transplantation
• prescribed by or in consultation with a neurologist, geneticist, or a physician who specializes in the treatment of amyloidosis
• not used concurrently with other medications indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis or transthyretin-mediated amyloidosis-cardiomyopathy (e.g., Amvuttra, Attruby, Onpattro, Wainua, or a tafamidis product)

Approval duration

1 year